Treatment of H. pylori Infection for Resistance of Double eradications

Treatment of H. pylori Infection for Resistance of Double eradications - Third Line Eradication Study (THIRD study)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012091

Enrollment

234

Registered

2015-10-21

Start date

2013-10-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients after unseccessful 1st and 2nd line eradication treatment

Interventions

LPZ 30mg bid + AMPC 750mg bid + STFX 100mg bid (1W) LPZ 30mg bid + AMPC 750mg bid + STFX 100mg bid (2W) LPZ 30mg bid + MNZ 500mg bid + STFX 100mg bid (1W)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients after failure of 1st-line eradcation (PPI+AMPC+CAM) and 2nd-line eradcation (PPI+AMPC+MNZ)

Exclusion criteria

Exclusion criteria: a history of antimicrobials after 2nd-line eradcation a history of PPI use 1 week before entry a history of NSAID or steriod use 1 month before entry a history of gastrointestinal surgery, the severe liver, renal, and cardiopulmonary dysfunctions a history of drug allergy

Design outcomes

Primary

Measure	Time frame
Eradication rate at 1 to 3 months after eradication treatment	—

Secondary

Measure	Time frame
side effect	—

Countries

Japan

Contacts

Public ContactMototsugu KATO

Hokkaido University Hospital Division of Endoscopy

m-kato@med.hokudai.ac.jp011-716-1161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026